Identification and monitoring of atypical PML/RARA fusion transcripts in acute promyelocytic leukemia

Licia Iaccarino, Mariadomenica Divona, Tiziana Ottone, Laura Cicconi, Serena Lavorgna, Claudia Ciardi, Valentina Alfonso, Serena Travaglini, Luca Facchini, Giuseppe Cimino, Eros Di Bona, Maria Teresa Voso, Francesco Lo-Coco

Research output: Contribution to journalArticle

Abstract

Once the diagnostic suspicion of acute promyelocytic leukemia (APL) has been raised, international guidelines recommend prompt initiation of tailored therapy and supportive care, while awaiting for genetic confirmation of the diagnosis, and the identification of the specific PML/RARA isoform by reverse transcriptase polymerase chain reaction (RT-PCR). Depending on the PML break point, usually located within intron 6, exon 6, or intron 3, different PML/RARA transcript isoforms may be generated, that is, long (bcr1), variant (bcr2), and short (bcr3), respectively. We report here the characterization of three APL cases harboring atypical PML/RARA transcripts, which were not clearly detectable after standard RT-PCR amplification. In all three cases, clinical, morphological, and immunophenotypic features were consistent with APL. Direct sequencing allowed the identification of atypical break points within the PML and RARA genes. Then, we designed a patient-specific quantitative real-time PCR for the atypical transcripts, which allowed for specific quantitative evaluation of minimal residual disease (MRD) during follow-up. Despite the rarity of APL cases with an atypical PML/RARA fusion, our study indicates that an integrated laboratory approach, employing several diagnostic techniques is crucial to timely diagnose APL. This approach allows prompt initiation of specific targeted treatment and reliable MRD monitoring in atypical APL cases.

Original languageEnglish
Pages (from-to)60-65
Number of pages6
JournalGenes Chromosomes and Cancer
Volume58
Issue number1
DOIs
Publication statusE-pub ahead of print - Dec 4 2018

Fingerprint

Acute Promyelocytic Leukemia
Residual Neoplasm
Reverse Transcriptase Polymerase Chain Reaction
Introns
Protein Isoforms
Real-Time Polymerase Chain Reaction
Exons
Guidelines
Therapeutics
Genes

Cite this

Identification and monitoring of atypical PML/RARA fusion transcripts in acute promyelocytic leukemia. / Iaccarino, Licia; Divona, Mariadomenica; Ottone, Tiziana; Cicconi, Laura; Lavorgna, Serena; Ciardi, Claudia; Alfonso, Valentina; Travaglini, Serena; Facchini, Luca; Cimino, Giuseppe; Di Bona, Eros; Voso, Maria Teresa; Lo-Coco, Francesco.

In: Genes Chromosomes and Cancer, Vol. 58, No. 1, 04.12.2018, p. 60-65.

Research output: Contribution to journalArticle

Iaccarino, L, Divona, M, Ottone, T, Cicconi, L, Lavorgna, S, Ciardi, C, Alfonso, V, Travaglini, S, Facchini, L, Cimino, G, Di Bona, E, Voso, MT & Lo-Coco, F 2018, 'Identification and monitoring of atypical PML/RARA fusion transcripts in acute promyelocytic leukemia', Genes Chromosomes and Cancer, vol. 58, no. 1, pp. 60-65. https://doi.org/10.1002/gcc.22708
Iaccarino, Licia ; Divona, Mariadomenica ; Ottone, Tiziana ; Cicconi, Laura ; Lavorgna, Serena ; Ciardi, Claudia ; Alfonso, Valentina ; Travaglini, Serena ; Facchini, Luca ; Cimino, Giuseppe ; Di Bona, Eros ; Voso, Maria Teresa ; Lo-Coco, Francesco. / Identification and monitoring of atypical PML/RARA fusion transcripts in acute promyelocytic leukemia. In: Genes Chromosomes and Cancer. 2018 ; Vol. 58, No. 1. pp. 60-65.
@article{97a41c615ab44d5dbcb1bb7f9b8c817b,
title = "Identification and monitoring of atypical PML/RARA fusion transcripts in acute promyelocytic leukemia",
abstract = "Once the diagnostic suspicion of acute promyelocytic leukemia (APL) has been raised, international guidelines recommend prompt initiation of tailored therapy and supportive care, while awaiting for genetic confirmation of the diagnosis, and the identification of the specific PML/RARA isoform by reverse transcriptase polymerase chain reaction (RT-PCR). Depending on the PML break point, usually located within intron 6, exon 6, or intron 3, different PML/RARA transcript isoforms may be generated, that is, long (bcr1), variant (bcr2), and short (bcr3), respectively. We report here the characterization of three APL cases harboring atypical PML/RARA transcripts, which were not clearly detectable after standard RT-PCR amplification. In all three cases, clinical, morphological, and immunophenotypic features were consistent with APL. Direct sequencing allowed the identification of atypical break points within the PML and RARA genes. Then, we designed a patient-specific quantitative real-time PCR for the atypical transcripts, which allowed for specific quantitative evaluation of minimal residual disease (MRD) during follow-up. Despite the rarity of APL cases with an atypical PML/RARA fusion, our study indicates that an integrated laboratory approach, employing several diagnostic techniques is crucial to timely diagnose APL. This approach allows prompt initiation of specific targeted treatment and reliable MRD monitoring in atypical APL cases.",
author = "Licia Iaccarino and Mariadomenica Divona and Tiziana Ottone and Laura Cicconi and Serena Lavorgna and Claudia Ciardi and Valentina Alfonso and Serena Travaglini and Luca Facchini and Giuseppe Cimino and {Di Bona}, Eros and Voso, {Maria Teresa} and Francesco Lo-Coco",
note = "{\circledC} 2018 Wiley Periodicals, Inc.",
year = "2018",
month = "12",
day = "4",
doi = "10.1002/gcc.22708",
language = "English",
volume = "58",
pages = "60--65",
journal = "Genes Chromosomes and Cancer",
issn = "1045-2257",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Identification and monitoring of atypical PML/RARA fusion transcripts in acute promyelocytic leukemia

AU - Iaccarino, Licia

AU - Divona, Mariadomenica

AU - Ottone, Tiziana

AU - Cicconi, Laura

AU - Lavorgna, Serena

AU - Ciardi, Claudia

AU - Alfonso, Valentina

AU - Travaglini, Serena

AU - Facchini, Luca

AU - Cimino, Giuseppe

AU - Di Bona, Eros

AU - Voso, Maria Teresa

AU - Lo-Coco, Francesco

N1 - © 2018 Wiley Periodicals, Inc.

PY - 2018/12/4

Y1 - 2018/12/4

N2 - Once the diagnostic suspicion of acute promyelocytic leukemia (APL) has been raised, international guidelines recommend prompt initiation of tailored therapy and supportive care, while awaiting for genetic confirmation of the diagnosis, and the identification of the specific PML/RARA isoform by reverse transcriptase polymerase chain reaction (RT-PCR). Depending on the PML break point, usually located within intron 6, exon 6, or intron 3, different PML/RARA transcript isoforms may be generated, that is, long (bcr1), variant (bcr2), and short (bcr3), respectively. We report here the characterization of three APL cases harboring atypical PML/RARA transcripts, which were not clearly detectable after standard RT-PCR amplification. In all three cases, clinical, morphological, and immunophenotypic features were consistent with APL. Direct sequencing allowed the identification of atypical break points within the PML and RARA genes. Then, we designed a patient-specific quantitative real-time PCR for the atypical transcripts, which allowed for specific quantitative evaluation of minimal residual disease (MRD) during follow-up. Despite the rarity of APL cases with an atypical PML/RARA fusion, our study indicates that an integrated laboratory approach, employing several diagnostic techniques is crucial to timely diagnose APL. This approach allows prompt initiation of specific targeted treatment and reliable MRD monitoring in atypical APL cases.

AB - Once the diagnostic suspicion of acute promyelocytic leukemia (APL) has been raised, international guidelines recommend prompt initiation of tailored therapy and supportive care, while awaiting for genetic confirmation of the diagnosis, and the identification of the specific PML/RARA isoform by reverse transcriptase polymerase chain reaction (RT-PCR). Depending on the PML break point, usually located within intron 6, exon 6, or intron 3, different PML/RARA transcript isoforms may be generated, that is, long (bcr1), variant (bcr2), and short (bcr3), respectively. We report here the characterization of three APL cases harboring atypical PML/RARA transcripts, which were not clearly detectable after standard RT-PCR amplification. In all three cases, clinical, morphological, and immunophenotypic features were consistent with APL. Direct sequencing allowed the identification of atypical break points within the PML and RARA genes. Then, we designed a patient-specific quantitative real-time PCR for the atypical transcripts, which allowed for specific quantitative evaluation of minimal residual disease (MRD) during follow-up. Despite the rarity of APL cases with an atypical PML/RARA fusion, our study indicates that an integrated laboratory approach, employing several diagnostic techniques is crucial to timely diagnose APL. This approach allows prompt initiation of specific targeted treatment and reliable MRD monitoring in atypical APL cases.

U2 - 10.1002/gcc.22708

DO - 10.1002/gcc.22708

M3 - Article

C2 - 30421475

VL - 58

SP - 60

EP - 65

JO - Genes Chromosomes and Cancer

JF - Genes Chromosomes and Cancer

SN - 1045-2257

IS - 1

ER -